Alembic Pharmaceuticals has secured final approval from the US Food and Drug Administration for its generic version of levothyroxine sodium tablets, a widely prescribed treatment for hypothyroidism. The approval covers multiple dosage strengths and positions the company to expand its footprint in the highly competitive US generics market. The medication is therapeutically equivalent to Synthroid, a leading thyroid replacement therapy marketed by AbbVie.